Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Cullinan Therapeutics Inc (NASDAQ: CGEM) was $6.91 for the day, down -10.49% from the previous closing price of $7.72. In other words, the price has decreased by -$10.49 from its previous closing price. On the day, 1.45 million shares were traded. CGEM stock price reached its highest trading level at $7.7 during the session, while it also had its lowest trading level at $6.615.
Ratios:
Our analysis of CGEM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.83 and its Current Ratio is at 9.83. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $30.UBS initiated its Buy rating on October 24, 2024, with a $30 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 25 ’25 when Jones Jeffrey Alan sold 4,895 shares for $8.53 per share. The transaction valued at 41,754 led to the insider holds 174,164 shares of the business.
AHMED NADIM sold 12,529 shares of CGEM for $106,872 on Feb 25 ’25. The President and CEO now owns 430,621 shares after completing the transaction at $8.53 per share. On Feb 25 ’25, another insider, Michaelson Jennifer, who serves as the Chief Scientific Officer of the company, sold 3,756 shares for $8.53 each. As a result, the insider received 32,039 and left with 142,004 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CGEM now has a Market Capitalization of 408204096 and an Enterprise Value of 144241040.
Stock Price History:
The Beta on a monthly basis for CGEM is -0.08, which has changed by -0.6156841 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, CGEM has reached a high of $19.66, while it has fallen to a 52-week low of $6.85. The 50-Day Moving Average of the stock is -10.50%, while the 200-Day Moving Average is calculated to be -24.48%.
Shares Statistics:
CGEM traded an average of 348.68K shares per day over the past three months and 504500 shares per day over the past ten days. A total of 59.07M shares are outstanding, with a floating share count of 36.28M. Insiders hold about 38.59% of the company’s shares, while institutions hold 70.66% stake in the company. Shares short for CGEM as of 1755216000 were 5845639 with a Short Ratio of 16.76, compared to 1752537600 on 5884616. Therefore, it implies a Short% of Shares Outstanding of 5845639 and a Short% of Float of 11.450000000000001.
Earnings Estimates
Its stock is currently analyzed by 8.0 different market analysts. The consensus estimate for the next quarter is -$0.91, with high estimates of -$0.83 and low estimates of -$1.02.
Analysts are recommending an EPS of between -$3.31 and -$4.01 for the fiscal current year, implying an average EPS of -$3.67. EPS for the following year is -$3.62, with 7.0 analysts recommending between -$2.59 and -$4.4.
